Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Department of Health Sciences and Public Health, Section of Hygiene, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Int J Environ Res Public Health. 2022 Jun 26;19(13):7848. doi: 10.3390/ijerph19137848.
Vaccinations generate health, economic and social benefits in both vaccinated and unvaccinated populations. The aim of this study was to conduct a cost-benefit analysis to estimate the costs and benefits associated with the COVID-19 vaccination campaign for health workers in Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG). The analysis included 5152 healthcare workers who voluntarily received the Pfizer-BioNTech COVID-19 vaccine, divided into physicians, nurses and other health workers. Data about vaccine cost, administration and materials were derived from administrative databases of the FPG from 28 December 2020 to 31 March 2021. The costs associated with the COVID-19 vaccination campaign amounted to EUR 2,221,768, while the benefits equaled EUR 10,345,847. The benefit-to-cost ratio resulted in EUR 4.66, while the societal return on investment showed a ratio of EUR 3.66. The COVID-19 vaccination campaign for health workers in FPG has high social returns and it strengthens the need to inform and update decision-making about the economic and social benefits associated with a vaccination campaign. Health economic evaluations on vaccines should always be considered by decision-makers when considering the inclusion of a new vaccine into the national program.
疫苗接种在接种者和未接种者人群中都产生了健康、经济和社会效益。本研究旨在进行成本效益分析，以估算 Fondazione Policlinico Universitario Agostino Gemelli IRCCS（FPG）卫生工作者 COVID-19 疫苗接种活动相关的成本和效益。该分析包括 5152 名自愿接种辉瑞-生物科技 COVID-19 疫苗的卫生工作者，分为医生、护士和其他卫生工作者。疫苗成本、管理和材料的数据来自 FPG 的行政数据库，时间范围为 2020 年 12 月 28 日至 2021 年 3 月 31 日。COVID-19 疫苗接种活动的相关成本为 222.1768 万欧元，而效益则达到 1034.5847 万欧元。效益成本比达到 4.66，而社会投资回报率则为 3.66。FPG 卫生工作者的 COVID-19 疫苗接种活动具有很高的社会效益，这进一步加强了对与疫苗接种活动相关的经济和社会效益进行信息告知和更新决策的必要性。在考虑将新疫苗纳入国家计划时，决策者应始终考虑疫苗的健康经济评估。
